Effective adenoviral transfer of IκBα into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-κB dependent

Journal of Rheumatology

Volumn 27, Issue 9, 2000, Pages 2078-2089

  Bondeson, J ^a   Brennan, F ^a   Foxwell, B ^a   Feldmann, M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Fibroblasts; Matrix metalloproteinases; Nuclear factor b; Rheumatoid arthritis; Stromelysin

Indexed keywords

COLLAGENASE; COLLAGENASE 3; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADENOVIRUS; ARTICLE; CARTILAGE DEGENERATION; CHONDROSARCOMA; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INDUCTION; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; VIRUS TRANSMISSION;

ARTHRITIS, RHEUMATOID; CHONDROSARCOMA; CYTOKINES; DNA-BINDING PROTEINS; FIBROBLASTS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-1; MATRIX METALLOPROTEINASES; NF-KAPPA B; PHORBOL ESTERS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033812222     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α
2. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α
3. Anti-tumor necrosis factor α therapy of rheumatoid arthritis
4. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
5. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
6. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
7. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
8. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
9. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice
10. Metalloproteinases and their inhibitors in matrix remodelling
11. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction
12. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3
13. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium
14. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP- 1), and MMP- 1/TIMP- 1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers
15. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): Correlation with rheumatoid arthritis
16. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases in synovial lining cells of rheumatoid synovium
17. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP) and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis
18. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation
19. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy
20. Tumour necrosis factor-α stimulates resorption and inhibits synthesis of proteoglycan in cartilage
21. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and their natural inhibitor, TIMP, in rheumatoid human synovial fibroblasts
22. Regulation of matrix metalloproteinase gene expression
23. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
24. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation
25. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene
26. Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes
27. Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin-1
28. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts
29. Regulation of collagenase gene expression by IL-1 beta requires transcriptional and post-transcriptional mechanisms
30. src-related tyrosine kinases regulate transcriptional activation of the interstitial collagenase gene, MMP-1, in interleukin-1-stimulated synovial fibroblasts
31. Association of interleukin-1-induced, NFκB DNA-binding activity with collagenase gene expression in human gingival fibroblasts
32. Nuclear factor κB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1β-stimulated synovial fibroblasts
33. Evidence that suppression of IL-1 induced collagenase mRNA expression by dihomo-γ-linolenic acid (DGLA) involves inhibition of NFκB binding
34. Inhibition of gingival collagenase gene expression by dexamethasone
35. Efficient adenoviral infection with IκBα reveals that macrophage TNFα production in rheumatoid arthritis is NF-κB dependent
36. Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: LPS- but no zymosan-induced proinflammatory cytokines are inhibited, but IL-10 is inhibited
37. A new approach to defining therapeutic targets: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium, but spares anti-inflammatory mediators
38. Inhibition of endothelial cell activation by adenovirus-mediated expression of IκBα, an inhibitor of the transcription factor NF-κB
39. Transcription factors NF-IL-6 and NF-κB synergistically activate transcription of the inflammatory cytokines interleukin 6 and interleukin 8
40. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-κB
41. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production
42. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
43. Methods for construction of adenovirus vectors
44. Interleukin-4 inhibits kappa light chain expression and NFκB activation but not IκBα degradation in 70Z/3 murine pre-B cells
45. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli LacZ
46. Identification of novel factors that bind to the PRD I region of the human beta-interferon promoter
47. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist
48. Efficient transfer of genes into senescent cells by adenovirus vectors via highly expressed αVβ5 integrin
49. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-κB
50. Transplantation of transduced chondrocytes protects articular cartilage from interleukin-1-induced extracellular matrix degradation
51. Resurfacing of articular cartilage explants with genetically-modified human chondrocytes in vitro
52. Adenovirus vector-mediated gene transduction to chondrocytes: In vitro evaluation of therapeutic efficacy of transforming growth factor-β1 and heat shock protein 70 gene transduction
53. Synergistic apregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription Factor NF-κB
54. Kinetics of adenovirus-mediated gene transfer to human lung fibroblasts
55. Involvement of a NF-kappa-B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines
56. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1 alpha
57. 1 alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts
58. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity TIMP-1/EPA)
59. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds
60. Aggrecanase. A target for the design of inhibitors of cartilage degradation
61. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint